Related Experiment Video

Updated: Aug 10, 2026

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function
10:28

Interventional Diagnostic Procedure: A Practical Guide for the Assessment of Coronary Vascular Function

Published on: March 15, 2022

Vascular dementia: potential of antiplatelet agents in prevention

H Chabriat1, M G Bousser

  • 1Department of Neurology, Hôpital Lariboisière, Paris, France. hugues.chabriat@lrb.ap-hop-paris.fr

European Neurology
|March 15, 2006
PubMed

Insights

Vascular dementia (VaD) has multiple causes, including stroke and small vessel disease. Antiplatelet drugs, commonly used for stroke prevention, have unproven efficacy in preventing VaD and cognitive decline.

Area of Science:

  • Neurology
  • Vascular Neurology
  • Geriatrics

Background:

  • Vascular dementia (VaD) is a clinicoradiological syndrome with diverse etiologies.
  • Causes include large vessel occlusion, small vessel disease, hypoperfusion, and hemorrhagic lesions.
  • Current VaD prevention strategies focus on stroke prevention through risk factor management and antithrombotic drugs.

Purpose of the Study:

  • To review the causes and prevention of vascular dementia.
  • To evaluate the role of antiplatelet drugs in preventing VaD and cognitive impairment.
  • To highlight the need for prospective studies on antiplatelet efficacy in at-risk populations.

Main Methods:

  • Literature review of VaD causes and prevention strategies.
  • Analysis of the current evidence on antiplatelet drug efficacy for VaD prevention.
  • Identification of knowledge gaps and future research directions.

Main Results:

  • Vascular dementia results from various ischemic and hemorrhagic lesions.
  • Antiplatelet drugs are widely used for stroke prevention but their efficiency in preventing VaD is not proven.
  • Evidence is lacking regarding the benefit of antiplatelet drugs in patients at risk of VaD.

Conclusions:

  • Effective prevention of VaD requires comprehensive stroke prevention strategies.
  • Prospective studies are crucial to determine the efficacy of antiplatelet drugs in preventing cognitive impairment in at-risk VaD patients.
  • Further research is needed to establish the role of antiplatelet therapy in the management of vascular dementia.

More Related Videos

Ferric Chloride-induced Murine Thrombosis Models10:37

Ferric Chloride-induced Murine Thrombosis Models

Published on: September 5, 2016

Related Concept Videos

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Dementia l: Introduction01:22

Dementia l: Introduction

Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...